CE marking and first commercialization

Biomaneo has obtained CE marking for its first product NeoSickle® and has signed its first sales contract with the CHRU of Lille for the sickle cell disease high throughput screening.

The production of the first 60 kits NeoSickle® for the CHRU of Lille has been performed in the new Biomaneo premises.

A significant step that comes to reward the involvement and the quality of the job accomplished by our teams for months.